Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy
about
Protein kinase cascades in the regulation of cardiac hypertrophyPKC translocation and ERK1/2 activation in compensated right ventricular hypertrophy secondary to chronic emphysemaProtein kinase C mechanisms that contribute to cardiac remodellingPKCepsilon activation induces dichotomous cardiac phenotypes and modulates PKCepsilon-RACK interactions and RACK expressionPhosphorylation or glutamic acid substitution at protein kinase C sites on cardiac troponin I differentially depress myofilament tension and shortening velocityInhibition of PKC phosphorylation of cTnI improves cardiac performance in vivoAblation of the cardiac-specific gene leucine-rich repeat containing 10 (Lrrc10) results in dilated cardiomyopathyFosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C epsilon and components of its signaling complexPKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2)Combination of ketamine and xylazine exacerbates cardiac dysfunction in severely scalded rats during the shock stage.PKCβII modulation of myocyte contractile performance.Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphorylation.Up-regulation of endothelin type B receptors in the human internal mammary artery in culture is dependent on protein kinase C and mitogen-activated kinase signaling pathwaysMammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats.Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?Differential and conditional activation of PKC-isoforms dictates cardiac adaptation during physiological to pathological hypertrophy.Activation of protein kinase C (PKC)α or PKCε as an approach to increase morphine tolerance in respiratory depression and lethal overdoseMineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".A mathematical model of the electrophysiological alterations in rat ventricular myocytes in type-I diabetes.Ultrasound imaging: principles and applications in rodent research.Challenges in small animal noninvasive imaging.Cardiac hypertrophy and failure: lessons learned from genetically engineered mice.Protein kinase Cθ is required for cardiomyocyte survival and cardiac remodeling.Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy.Compensatory renal hypertrophy following uninephrectomy is calcineurin-independent.βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failureThe sarcomeric Z-disc and Z-discopathies.Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylationDistinctive activation mechanisms and functions for protein kinase Cdelta.PKCε promotes cardiac mitochondrial and metabolic adaptation to chronic hypobaric hypoxia by GSK3β inhibition.Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophyCombined cardiomyocyte PKCδ and PKCε gene deletion uncovers their central role in restraining developmental and reactive heart growthFunctional consequences of sarcomeric protein abnormalities in failing myocardium.Reactive oxygen species in cardiac signalling: from mitochondria to plasma membrane ion channels.Echocardiographic characterization of the cardiovascular phenotype in rodent models.Protein kinase C depresses cardiac myocyte power output and attenuates myofilament responses induced by protein kinase ACardiac actions of protein kinase C isoformsEthanol for cardiac ischemia: the role of protein kinase c.Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.Protein kinase C zeta. A novel regulator of both phosphorylation and de-phosphorylation of cardiac sarcomeric proteins.
P2860
Q24518494-E0FBCF8C-D2B3-4A6C-8DCD-F2F09B21654AQ24810204-811A47D4-F404-4847-8F5C-70C045B0DC76Q28075729-B95A41A5-B592-43B0-9781-88D4A22B21B8Q28200094-7E2D62BF-4B03-4ED2-9CF3-3C8DE4EB5FA4Q28205242-61FC71EB-876A-4FF5-BA10-37D47713000AQ28238928-E749C597-5A40-4234-A66F-3FD5EA0B9BC7Q28512007-1416AE02-FE23-4F27-B812-DA96D09F9A11Q28567017-A041AF58-EF8B-4ED1-A094-F43315953D13Q28567395-50F896FE-48F8-4AD5-91AE-3CDCA5179013Q30448246-23099556-B1FC-4746-BF58-AE1CCDB11715Q30524184-492F7926-5CB8-490D-9824-22258448AACEQ33214227-465903CC-0158-49E7-9614-429C65DB2675Q33367779-C473B8E8-7942-4877-BEE3-3625118229BCQ33576908-AFCC6279-C22E-4827-A3D5-2BDDD4CE95EAQ33807091-8D32EA60-F2B4-4937-8A2C-D684F4910F28Q34035413-8E82E7FB-07E1-4797-AEE7-DB4B8CB1EFBBQ34121723-50651FD8-D225-4416-9BA6-0FEC770FF6FBQ34121798-13306FC4-AE7A-412E-8E86-8842839CC862Q34180327-C0D28557-CCAD-4A71-AEC4-C8EDFE5B9441Q34282862-ECE44C9C-CC0B-4BBB-A132-C27AC9070729Q34282869-D6A4A404-6A0A-4890-9B92-256611853904Q34418993-D210FE2F-A98E-4B5A-935E-590C22AB8329Q34545363-5E46103D-9A55-4307-9FEE-E539D8082608Q34766977-FEDC7629-3849-44F4-968A-952A1CD28352Q34998348-BF2E5C75-E759-4E38-BD5C-340A19D334E0Q35103455-95BA393A-47CC-489D-BC3B-D099D8B05D65Q35418525-88B5B74B-4DB2-4F38-89C5-8EEC52624122Q35634087-E2C46DB2-112A-458F-ABBC-7EDE045BF918Q35921462-4F4D6C4A-50DD-4053-BED3-489738A793C8Q36138182-DA92345F-D70E-4921-8DDD-B6F8D08FF0C7Q36322902-F3B5A401-BC3B-42A9-B4D6-D57B92A78C90Q36367548-3437C9FD-C113-4573-B3A9-998062E20702Q36369931-465BBE4F-9422-43BE-9A22-D4E331E8CC5DQ36381493-F7970FBB-A6F4-44ED-9960-304EE41CE64FQ36409460-4E3ED14C-A83B-44F2-B07E-FDC1F41DADA0Q36599563-BB3543F3-6536-4C19-B296-146D7C079BDCQ36638771-32C21E87-1E05-4FE3-A0A8-C38B00D384EBQ36694026-A31F8B6B-53F2-4855-A70B-EBF3679479BFQ36745702-2BF13391-7C22-40D1-BDDC-48DB092ACB04Q37001822-FEB63E2F-8A9C-47A4-97DC-4A77FCF79E25
P2860
Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@ast
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@en
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@nl
type
label
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@ast
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@en
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@nl
prefLabel
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@ast
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@en
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@nl
P2093
P1433
P1476
Transgenic overexpression of c ...... concentric cardiac hypertrophy
@en
P2093
P304
P356
10.1161/01.RES.86.12.1218
P407
P577
2000-06-23T00:00:00Z